TGFB3: Transforming growth factor beta-3 proprotein
Transforming growth factor beta-3 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-3 (TGF-beta-3) chains, which constitute the regulatory and active subunit of TGF-beta-3, respectively. {ECO:0000250|UniProtKB:P01137, ECO:0000250|UniProtKB:P04202}.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on TGFB3, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Fresolimumab | Phase 2 | Sanofi | Antibody | InhibitorTransforming growth factor beta-3 inhibitor | 0 |
- Rienhoff syndrome0.79
- Arrhythmogenic right ventricular dysplasia 10.67
- Loeys-Dietz syndrome0.65
- Familial thoracic aortic aneurysm and aortic dissection0.65
- Myelodysplastic syndrome0.56
- Anemia0.56
- Beta thalassemia0.54
- Anemia (phenotype)0.40
- Pulmonary emphysema0.37
- Familial isolated arrhythmogenic ventricular dysplasia, biventricular form0.37
- Thalassemia0.37
- Familial isolated arrhythmogenic ventricular dysplasia, left dominant form0.37
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712903, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P10600, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets